ICICI Prudential Asset Management Co Ltd Cuts Stock Position in Bristol Myers Squibb Company $BMY

ICICI Prudential Asset Management Co Ltd lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 21.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 142,849 shares of the biopharmaceutical company’s stock after selling 39,000 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in Bristol Myers Squibb were worth $7,705,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Norges Bank purchased a new stake in Bristol Myers Squibb in the 4th quarter worth $1,947,272,000. Bank of New York Mellon Corp increased its holdings in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after acquiring an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC increased its holdings in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Man Group plc increased its holdings in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in Bristol Myers Squibb by 530.6% in the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock worth $245,946,000 after acquiring an additional 4,588,601 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Erste Group’s FY2026 earnings estimate for Bristol Myers Squibb stayed in line with Wall Street expectations, reinforcing the view that current earnings are stable and the stock remains attractively valued.
• Positive Sentiment: Zacks highlighted Bristol Myers Squibb as a top-ranked value stock, which may attract income- and value-focused investors looking for defensive healthcare exposure.
• Neutral Sentiment: Analyst revisions were mixed overall, with a small downward tweak to FY2027 EPS but a slightly higher FY2026 forecast, suggesting limited near-term estimate pressure.
• Negative Sentiment: Takeda reported that its AI-designed psoriasis drug, zasocitinib, outperformed BMY’s approved psoriasis treatment Sotyktu in a head-to-head study, raising competitive concerns for one of Bristol Myers Squibb’s growth products. Article Title

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.05% of the stock is owned by insiders.

Bristol Myers Squibb Trading Up 2.4%

Shares of BMY stock opened at $56.96 on Friday. The company’s 50-day moving average price is $57.83 and its 200-day moving average price is $56.87. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The stock has a market cap of $116.31 billion, a price-to-earnings ratio of 16.00, a PEG ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BMY shares. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Cantor Fitzgerald boosted their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Finally, Barclays started coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.